Introduction
The inappropriate use of nebulised beta-2-adrenergic agonist drugs has been proposed as a possible factor contributing to asthma mortality in New Zealand.' This hypothesis was supported by the finding of a subsequent study which investigated the management of patients dying from asthma in New Zealand.2'3 In those patients who had a home nebuliser and its use during the final attack was known, over one-third had used it inappropriately.2 Indeed, over one-quarter of all the patients who died from asthma during the two year period of this study had a home nebuliser available for self-administration of beta-adrenergic agonist drugs. This is in marked contrast with the situation in England, where similar asthma mortality studies have demonstrated that death from asthma outside hospital is not associated with home nebuliser use. 4'5 Analysis of the specific beta-2 adrenergic agonist self-administered by the patients who died, demonstrated that there was a significantly greater proportion offenoterol than salbutamol used when compared with national sales of these drugs, suggesting that these agents may differ in their extra-pulmonary effects or toxicity. We HR; QS2I is the QS index corrected for heart rate).8 From the ECG the QT interval and T-wave amplitude were measured. The end of the QT interval was measured by extrapolating the slope of the T-wave to the baseline (P-P interval). This interval (QTc) was corrected for the heart rate using the Bazett formula.9 The percentage change in T-wave amplitude from the control measurements (AT%) was noted on each day. Blood pressure was measured automatically using a Vita Stat recorder.
All subjects gave written informed consent and the study was approved by the Wellington Hospital Research Ethical Committee.
Statistical analysis
A three-way analysis of variance with subject, treatment and time effects was performed on the change from control data. The significance level was adjusted for multiple comparisons by using Bonferroni's inequality (P <0.05 number of comparisons).'°Hence, when a significant treatment-time interaction was present, a probability value of P <0.0017 was considered significant when comparisions between treatments were made at each time.
Results
There were no significant differences in the control measurements between the treatment days (Table   I) .
When compared to placebo (see Figure 1 and Table II ), all the active agents increased heart rate, decreased electromechanical systole (QS2I), pre- Figure 1 Effect of the treatments on heart rate (HR), total electromechanical systole (QS2I), QTc interval and systolic blood pressure (SBP). 0, Placebo; I, fenoterol; 0, salbutamol; 0, terbutaline. Although the cardiovascular effects of salbutamol and terbutaline are similar in magnitude, there were significant differences in their duration of action. The effects due to terbutaline were ofslower onset and of greater duration than those following salbutamol. As a result, at the end of the 90 minute time course the cardiovascular effects ofterbutaline were greater than those after salbutamol. We have observed similar differences in the time courses of the hypokalaemic effects of these agents when administered to some of these subjects. '5 This difference is likely to be due to differences in bioavailability which in turn is likely to be due to differences in the preparation of these agents.
These results are of importance as they point to major differences in the clinical extra-pulmonary effects of these agents. Fenoterol 
